Open AccessBreast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response
Author(s) -
Natsuko Onishi,
Wen Li,
David C. Newitt,
Roy Harnish,
Fredrik Strand,
Alex Nguyen,
Vignesh A. Arasu,
Jessica Gibbs,
Ella F. Jones,
Lisa J. Wilmes,
John Kornak,
Bonnie N. Joe,
Elissa R. Price,
Haydee OjedaFournier,
Mohammad Eghtedari,
Kathryn W. Zamora,
Stefanie Woodard,
Heidi Umphrey,
Michael T. Nelson,
An L. Church,
Patrick J. Bolan,
Theresa Kuritza,
Kristen Ward,
Kevin Morley,
Dulcy Wolverton,
Kelly Fountain,
Dan Lopez Paniagua,
Lara A. Hardesty,
Kathleen R. Brandt,
Elizabeth S. McDonald,
Mark Rosen,
Despina Kontos,
Hiroyuki Abé,
Deepa Sheth,
Erin Crane,
Charlotte Dillis,
Pulin Sheth,
Linda Hovanessian-Larsen,
Dae Hee Bang,
Bruce A. Porter,
Karen Y. Oh,
Neda Jafarian,
Luminita A. Tudorica,
Bethany L. Niell,
Jennifer S. Drukteinis,
Mary S. Newell,
Marina Giurescu,
Elise Berman,
Constance D. Lehman,
Savannah C. Partridge,
Kimberly A. Fitzpatrick,
Marisa H. Borders,
Wei Tse Yang,
Başak E. Doğan,
Sally Goudreau,
Thomas L. Chenevert,
Christina Yau,
Angela DeMichele,
Donald A. Berry,
Laura J. Esserman,
Nola M. Hylton
Publication year - 2021
Publication title -
radiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.118
H-Index - 295
eISSN - 1527-1315
pISSN - 0033-8419
DOI - 10.1148/radiol.2021203645
Subject(s) - medicine , breast cancer , chemotherapy , magnetic resonance imaging , breast mri , retrospective cohort study , neoadjuvant therapy , exact test , nuclear medicine , radiology , cancer , mammography
Background Suppression of background parenchymal enhancement (BPE) is commonly observed after neoadjuvant chemotherapy (NAC) at contrast-enhanced breast MRI. It was hypothesized that nonsuppressed BPE may be associated with inferior response to NAC. Purpose To investigate the relationship between lack of BPE suppression and pathologic response. Materials and Methods A retrospective review was performed for women with menopausal status data who were treated for breast cancer by one of 10 drug arms (standard NAC with or without experimental agents) between May 2010 and November 2016 in the Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2, or I-SPY 2 TRIAL (NCT01042379). Patients underwent MRI at four points: before treatment (T0), early treatment (T1), interregimen (T2), and before surgery (T3). BPE was quantitatively measured by using automated fibroglandular tissue segmentation. To test the hypothesis effectively, a subset of examinations with BPE with high-quality segmentation was selected. BPE change from T0 was defined as suppressed or nonsuppressed for each point. The Fisher exact test and the Z tests of proportions with Yates continuity correction were used to examine the relationship between BPE suppression and pathologic complete response (pCR) in hormone receptor (HR)-positive and HR-negative cohorts. Results A total of 3528 MRI scans from 882 patients (mean age, 48 years ± 10 [standard deviation]) were reviewed and the subset of patients with high-quality BPE segmentation was determined (T1, 433 patients; T2, 396 patients; T3, 380 patients). In the HR-positive cohort, an association between lack of BPE suppression and lower pCR rate was detected at T2 (nonsuppressed vs suppressed, 11.8% [six of 51] vs 28.9% [50 of 173]; difference, 17.1% [95% CI: 4.7, 29.5]; P = .02) and T3 (nonsuppressed vs suppressed, 5.3% [two of 38] vs 27.4% [48 of 175]; difference, 22.2% [95% CI: 10.9, 33.5]; P = .003). In the HR-negative cohort, patients with nonsuppressed BPE had lower estimated pCR rate at all points, but the P values for the association were all greater than .05. Conclusions In hormone receptor-positive breast cancer, lack of background parenchymal enhancement suppression may indicate inferior treatment response. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Philpotts in this issue.